Tumor information | Total, n | ESBL n (%) | Non-ESBL n (%) | P-value |
---|---|---|---|---|
Tumor types | 358 | 160 (44.7) | 198 (55.3) | 0.001 |
Urological cancer | 64 | 40 (62.5) | 24 (37.5) | 0.002 |
Prostate cancer | 18 | 14 (77.8) | 4 (22.2) | |
Bladder cancer | 31 | 20 (64.5) | 11 (35.5) | |
Ureter and renal pelvis cancer | 4 | 2 (50.0) | 2 (50.0) | |
Penile cancer | 2 | 1 (50.0) | 1 (50.0) | |
Renal cancer | 9 | 3 (33.3) | 6 (66.7) | |
Gynecological cancer | 73 | 37 (50.7) | 36 (49.3) | 0.248 |
Cervical caner | 54 | 29 (53.7) | 25 (46.3) | |
Ovarian and ureter cancer | 14 | 7 (50.0) | 7 (50.0) | |
Endometrial cancer | 5 | 1 (20.0) | 4 (80.0) | |
Gastrointestinal neoplasms | 85 | 38 (44.7) | 47 (55.3) | 0.998 |
Rectal cancer | 33 | 18 (54.5) | 15 (45.5) | |
Colorectal cancer | 19 | 9 (47.4) | 10 (52.6) | |
Esophagus cancer | 9 | 3 (33.3) | 6 (66.7) | |
Stomach cancer | 9 | 3 (33.3) | 6 (66.7) | |
Liver cancer | 6 | 2 (33.3) | 4 (66.7) | |
Pancreatic cancer | 6 | 2 (33.3) | 4 (66.7) | |
Gallbladder cancer | 3 | 1 (33.3) | 2 (66.7) | |
Hematologic malignancy | 24 | 8 (33.3) | 16 (66.7) | 0.247 |
Lymphoma | 24 | 8 (33.3) | 16 (66.7) | |
Thoracic neoplasms | 89 | 25 (28.1) | 64 (71.9) | < 0.001 |
Breast cancer | 19 | 7 (36.8) | 12 (63.2) | |
Lung cancer | 70 | 18 (25.7) | 52 (74.3) | |
Other | 23 | 12 (52.2) | 11 (47.8) | 0.456 |
Pathological type | 358 | 160 | 198 | 0.137 |
Adenomatous carcinoma | 175 | 71 (40.6) | 104 (59.4) | |
Squamous cell carcinoma | 74 | 40 (54.1) | 34 (45.9) | |
Neuroendocrine carcinoma | 31 | 11 (35.5) | 20 (64.5) | |
Urothelial carcinoma | 31 | 19 (61.3) | 12 (38.7) | |
Non-Hodgkin lymphoma | 24 | 8 (33.3) | 16 (66.7) | |
Sarcoma | 8 | 4 (50.0) | 4 (50.0) | |
Other | 15 | 7 (46.7) | 8 (53.3) | |
Clinical stages | 358 | 160 | 198 | 0.028 |
I | 24 | 10 (41.7) | 14 (58.3) | |
II | 32 | 11 (34.4) | 21 (65.6) | |
III | 79 | 26 (32.9) | 53 (67.1) | |
IV | 223 | 113 (50.7) | 110 (49.3) |